AnalysisNews

RNAZ today

$1.40+$0.05 (+3.70%)close Nov 17, 2026

Trend

DailyDowntrend (confirmed)

4 hourLeaning Bullish

1 hourDescending Triangle

15 minStrong Bearish

5 minExpanding

Daily trend turns up above $1.95

Key levels

Resistance$1.91

Resistance$1.55

Support$1.33

Latest news & SEC filings

NewsTransCode Therapeutics hires Tungsten Advisors for strategic review

All RNAZ news →

About Transcode Therapeutics

Transcode Therapeutics develops RNA-based drugs and immune-focused cancer therapies, aimed at serious and late-stage tumors. Its main candidate, TTX-MC138, targets a cancer-linked microRNA and has finished an early human study. The company is also pursuing a vaccine candidate, a virus-based immune therapy program, and, via its Polynoma unit, the experimental melanoma vaccine Seviprotimut-L. It serves cancer patients and is based in the United States.

Based on the company's 10-K filed Apr 15, 2026.

Nasdaq · Healthcare

Transcode Therapeutics, Inc. (RNAZ)

$1.40+0.05 (+3.70%)
WATCHLISTGrade: C+Risk: MEDIUM
1D5D1M1Y5YMaxSign up for all timeframes
1.431.541.641.751.40Oct 15Oct 23Nov 2Nov 10
High1.53
Low1.28
Open1.46
Volume33K
Avg Vol24K
VWAP1.38
30d High1.86
30d Low1.32
30d Chg-20.45%

What Is the Price Target for RNAZ?

SEPT Low Target

$0.00

SEPT Mid Target

$0.00

SEPT High Target

$0.00

Analyst Consensus

$0.00

Current: $1.49Upside: +0.0%Confidence: 20%Method: No Coverage

Is RNAZ a Buy or Sell Right Now?

48
Investability Score
WATCHLIST12-18 months

Test your own strategy on RNAZ

Describe your strategy in plain words, then scan, alert, backtest and paper trade it on RNAZ with SEPT’s own market data.

Start Free Trial →

Is RNAZ Overvalued or Undervalued?

Valuation Verdict

FAIR

Methods Used

P/B

Fair Value

$1.76

9

Moat Score

NONE

4/9

Piotroski Score

-1.2

Altman Z-Score

What Is Smart Money Doing with RNAZ?

Insider Signal

NEUTRAL

0 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

LOW

Signal: NEUTRAL

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See Smart Money Data →

RNAZ Growth Story

Revenue YoY

N/A%

3yr Revenue CAGR

N/A%

EPS Growth YoY

96.07%

FCF Growth YoY

-46.1%

Revenue Trend

UNKNOWN

Dark Pool Trades for RNAZ

PREVIEW

Recent off-exchange (dark pool) prints for RNAZ: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.

TimePriceSizeValueSide
20:39:26$1.391,000$$1KSELL
20:04:15$1.401,000$$1KSELL
19:53:00$1.531,500$$2KBUY
19:52:13$1.482,000$$3KBUY
19:31:47$1.371,000$$1KSELL

5 dark pool trades shown · $$9K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Transcode Therapeutics, Inc. (RNAZ) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

Your strategy, tested before real money.

Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.

Try SEPT Free for 7 Days →

RNAZ — frequently asked questions

What is RNAZ stock price today?

Transcode Therapeutics, Inc. (RNAZ) is at $1.40, up 3.70% (+$0.05) at the Nov 17, 2026 close.

Why is RNAZ stock moving today?

Latest RNAZ news — Oct 29, 2026: TransCode Therapeutics hires Tungsten Advisors for strategic review

Did RNAZ beat earnings?

RNAZ last reported on Aug 14, 2026: EPS -$7.17.

What are RNAZ support and resistance levels?

Support: $1.33. Resistance: $1.55, $1.91, $2.39.

What are insiders doing with RNAZ?

Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.

What is the latest news on RNAZ?

Oct 29, 2026: TransCode Therapeutics hires Tungsten Advisors for strategic review